Zhu Xiaolin, Ding Chien-Kuang C, Aggarwal Rahul R
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Curr Oncol Rep. 2025 Apr;27(4):362-374. doi: 10.1007/s11912-025-01643-9. Epub 2025 Feb 27.
Treatment-emergent neuroendocrine prostate cancer (NEPC) is aggressive and lethal. As androgen receptor signaling inhibitors (ARSIs) are increasingly used in earlier disease settings, treatment-emergent NEPC becomes more prevalent, and effective therapies are urgently needed. The purpose of this review was to summarize recent progress on emerging therapeutic targets of NEPC.
A multitude of therapeutic targets have emerged in NEPC over recent years. These targets may represent drivers of treatment-emergent lineage plasticity or simply be overexpressed on the surface of NEPC cells. Multiple modalities have been employed to drug these targets, with promising preclinical and clinical results. Treatment-emergent NEPC represents a distinct and clinically significant subset of castration-resistant prostate cancer (CRPC). Emerging therapeutic approaches have demonstrated encouraging efficacy and safety profiles, offering the potential to improve patient outcomes.
治疗引发的神经内分泌前列腺癌（NEPC）具有侵袭性且致命。随着雄激素受体信号抑制剂（ARSIs）越来越多地用于早期疾病治疗，治疗引发的NEPC变得更加普遍，迫切需要有效的治疗方法。本综述的目的是总结NEPC新兴治疗靶点的最新进展。
近年来，NEPC中出现了众多治疗靶点。这些靶点可能代表治疗引发的谱系可塑性驱动因素，或者仅仅在NEPC细胞表面过度表达。已经采用多种方法针对这些靶点进行药物研发，临床前和临床结果都很有前景。治疗引发的NEPC代表去势抵抗性前列腺癌（CRPC）中一个独特且具有临床意义的亚组。新兴的治疗方法已显示出令人鼓舞的疗效和安全性，有望改善患者预后。
